| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 17, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 17, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $28.00 | Hold | Canaccord Genuity |
| 7/14/2025 | $31.00 | Buy | BofA Securities |
| 7/14/2025 | $31.00 | Overweight | Analyst |
| 7/14/2025 | $32.00 | Buy | Guggenheim |
| 7/14/2025 | $33.00 | Outperform | Evercore ISI |
| 7/14/2025 | $32.00 | Buy | TD Cowen |
| 7/14/2025 | $38.00 | Buy | BTIG Research |
| 7/14/2025 | $34.00 | Buy | Citigroup |
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. This study explains why patient responses vary and reveals how resistance can evolve over time.
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximatel
SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00
BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00
Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will
IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)